Working Paper Communication Version 1 This version is not peer-reviewed

The Predictive Value of a Blood-Based RNA Signature for the Gemcitabine Response in Advanced Pancreatic Cancer

Version 1 : Received: 15 October 2020 / Approved: 21 October 2020 / Online: 21 October 2020 (11:53:07 CEST)

A peer-reviewed article of this Preprint also exists.

Piquemal, D.; Noguier, F.; Pierrat, F.; Bruno, R.; Cros, J. Predictive Values of Blood-Based RNA Signatures for the Gemcitabine Response in Advanced Pancreatic Cancer. Cancers 2020, 12, 3204. Piquemal, D.; Noguier, F.; Pierrat, F.; Bruno, R.; Cros, J. Predictive Values of Blood-Based RNA Signatures for the Gemcitabine Response in Advanced Pancreatic Cancer. Cancers 2020, 12, 3204.

Journal reference: Cancers 2020, 12, 3204
DOI: 10.3390/cancers12113204

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is expected to be the second cause of cancer death by 2022. For nearly 80% of patients, diagnosis occurs at an advanced, non-surgical stage, making such patients incurable. Gemcitabine is still an important component in PDAC treatment and is most often used as a backbone to test new targeted therapies and there is, to date, no routine biomarker to predict its efficacy. Samples from a phase III randomized trial were used to develop trough a large approach based on blood-based liquid biopsy, transcriptome profiling, and machine learning, a 9 gene predictive signature for gemcitabine sensitivity. Patients with a positive test (41.6%) had a significantly longer progression free survival (PFS) (3.8 months vs. 1.9 months p=0.03) and a longer overall survival (OS) (14.5 months vs. 5.1 p<0.0001). In multivariate analyses, this signature was independently associated with PFS (HR=0.5 (0.28-0.9) p=0.025) and OS (HR=0.39 (0.21-0.7) p=0.002).

Subject Areas

Pancreatic cancer; Predictive diagnosis; Liquid biopsy; gemcitabine

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.